Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT01324505
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT01272973
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT00851773
Effect of Renal Impairment on the Pharmacokinetics of NN9535
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT00833716
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Knoxville, Tennessee, United States
A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT00813020
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 415
- Registration Number
- NCT00696657
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Trowbridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.